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Summary
Severe heart failure and cerebral stroke are broadly asso-
ciated with the impairment of muscular function that con-
ventional treatments struggle to restore. New technologies
enable the construction of “smart” materials that could be
of great help in treating diseases where the main problem
is muscle weakness. These materials “behave” similarly
to biological systems, because the material directly con-
verts energy, for example electrical energy into movement.
The extension and contraction occur silently like in natural
muscles. The real challenge is to transfer this amazing tech-
nology into devices that restore or replace the mechanical
function of failing muscle. Cardiac assist devices based on
artificial muscle technology could envelope a weak heart
and temporarily improve its systolic function, or, if placed
on top of the atrium, restore the atrial kick in chronic atrial
fibrillation. Artificial sphincters could be used to treat ur-
inary incontinence after prostatectomy or faecal incontin-
ence associated with stomas. Artificial muscles can restore
the ability of patients with facial paralysis due to stroke or
nerve injury to blink. Smart materials could be used to con-
struct an artificial oesophagus including peristaltic move-
ment and lower oesophageal sphincter function to replace
the diseased oesophagus thereby avoiding the need for lap-
arotomy to mobilise stomach or intestine. In conclusion, in
the near future, smart devices will integrate with the human
body to fill functional gaps due to organ failure, and so cre-
ate a human chimera.
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Introduction
Heart failure and cerebral stroke are some of the most
dreadful and frequent diseases in high-developed countries
and, from the clinical point of view, are both associated
with impairment of muscular function. Conventional med-
ical and surgical treatments can barely restore the muscular
function in case of muscular necrosis or paralysis.
– Natural muscles self-repair, provide billions of work
cycles involving contraction of more than 25%, can increase
their strength and change stiffness in response to need, and
can even transform to become a source of essential nutrition-
al value for a hungry body. They convert the energy of aden-
osine triphosphate to mechanical energy with an exceptional
efficiency of about 45%. So far, scientists have been unable
to create materials or devices that reproduce exactly natur-
al muscle function and their working processes. However,
there are, smart materials that are the basis for many techno-
logies used in medicine, manufacturing, and defence that, in
specific configurations and with limited applications, could
reproduce at least part of natural muscle function. Scientists
define these materials as being “smart” because they react to
changes in stimuli such as temperature, medium pH, light or
magnetic fields and generate movements. The characterist-
ics of the ideal artificial muscle should be similar to those of
biological muscle. Biological muscles are optimised systems
that are relatively similar in all species and exhibit quick re-
action times with large linear forces. Biological muscle con-
traction, stimulated by electrochemical nerve conduction, is
caused by chemically induced reversible hydrogen bonding
between actin and myosin. An electroactive polymer acts
in the same way because the contraction and expansion of
the material follow ionic flows directed by an applied elec-
tric field [1–3]. A memory shape alloy reacts to the envir-
onmental temperature, quickly reorganising its three-dimen-
sional molecular structure and this process induces shape
changes that result in movement [1, 2]. However, even if
these smart materials seem to act like natural muscles, it
should be clear that we are still very far from being able to
reproduce Nature. Such materials could be of great help in
treating diseases where the main problem is the weakness of
the muscle, because, in specific conditions, smart materials
act as natural muscles. They “behave” similarly to biological
systems, therefore the definition of Biomimetics materials.
Contraction and expansion occur silently, because the mater-
ial directly converts a given form of energy such as electri-
city into movement.
Artificial muscle technology for
medical applications
Instead of reproducing nature by creating large macroscop-
ic movements by the combined effects of trillions of mo-
lecular actuators (the actin-myosin process), the artificial
muscle uses material deformations induced by environ-
mental changes.
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Shape memory alloys (SMAs)
These show properties that make them the ideal key com-
ponent of artificial muscle for medical application [1]. An
SMA is able of remembering a previously memorised
shape. It has to be deformed in its Martensitic (low tem-
perature) phase and subsequently heated to the high tem-
perature phase Austenite, e.g., in hot water or with an elec-
trical current [2]. The alloy generates a high force during
the phase change. Any system able to convert energy into
movement is defined actuator, thus, nitinol is used as actu-
ator in a huge number of applications. The shape change is
not restricted to pure bending. The most suitable actuation
mode has proven to be the linear contraction of a straight
wire actuator.
Nitinol, a nickel titanium (55% Ni, 45% Ti) alloy discovered
in 1962 in the United States Naval Ordnance Laboratory,
is biocompatible and extensively used for the endovascular
treatment of cardiovascular diseases (coronary stents, endo-
prostheses for the treatment of aortic aneurysms, etc.) be-
cause of its superelasticity. One of the key characteristics of
the Nitinol wires that could enable its use as actuator is that
the wires reduce their length up to 8%, very smoothly or ex-
tremely rapidly depending on the way the electric current is
applied and the transitional temperature reached. The form
of the energy wave applied to heat the wire determines the
velocity of the fiber contraction and the length of the con-
traction as well. Therefore, with the appropriate energy sup-
ply the wire acts like natural skeletal muscle (fig. 1). Nitinol
suitable for medical application has a transitional temperat-
ure below 50 °C and to avoid thermal lesions it has to be in-
sulated from the surrounding tissue.
An important quest is the energy supply. The actuation of
Nitinol wires needs a current of 450 mA and a voltage de-
pending on the length and the resistance of the wire, but usu-
ally lower than 24 V. Electrically driven actuators rely on
batteries, and this could restrict their clinical applications.
They operate with a very low efficiency, not exceeding 10%.
Electroactive polymers (EAP)
Electroactive polymer artificial muscles were developed at
SRI International (Menlo Park, California) in the 1990s.
They are functional materials that can be used as actuators
in active structures, in particular when large deformations
and low forces are required. Such actuators transform elec-
trical energy directly into mechanical work and produce
Figure 1
The above curves illustrate the extension relationship of a muscle
that is stretched (left) and an SMA spring actuator (right) at different
temperatures. The idea in this comparison is to identify a hysteresis
loop in both cases. Left: typical stress–muscle length extension
relationships, measured during 6 Cycles of 5, 10 and 15% length
extension at 25 μm s−1. Right: isothermal force-displacement
curves of an SMA spring actuator.
large strains. In ionic EAPs the activation forces are gener-
ated by diffusion of mobile ions under low current and usu-
ally only a few volts, which make them suitable for medic-
al applications [3]. Electroactive polymer artificial muscle
is composed of an inner core of a dielectric elastomer
film (e.g., silicone, acrylic, teflon) with a flexible electrode
coating placed on either side, usually made of gold. When
a DC voltage is applied to the electrodes, the elastomeric
polymer expands in a plane perpendicular to the force due
to the attraction between the electrodes. When the electrical
current is released, the artificial muscle contracts back to its
original shape, thus converting the electrostatic force into
mechanical work [4]. Another advantage of EPAs consists
in the extreme variability of shapes and structures they can
be fashioned: string, spiral or sheet that can also be bended
or twisted.
However, actuator performance typically degrades after a
few thousand cycles when the actuator is operated at high
strains and high mechanical loads. Energy conversion is
low (typically less than 1%) but could be improved drastic-
ally by avoiding electrolyte electrolysis and harvesting
stored electrical energy. An artificial muscle that takes the
energy supply directly from the blood stream analogous to
natural muscle, represents a major step forward in expand-
ing its clinical application. Nature’s technique of convert-
ing the chemical energy of a high-energy-density fuel to
mechanical work has advantages, which can be partially
achieved by driving electrical actuators with fuel cells.
Such a system exists and is called breathing artificial
muscle [5], but is still far from clinical applications.
Potential clinical applications
The real challenge is to transfer such amazing technologies
into implantable devices that integrate with the human
body to fill the functional gaps arising from organ or sys-
tem failure, therefore creating “human chimera”.
Cardiac assist devices based on artificial muscles
The first use of Nitinol wires as artificial muscle for an ar-
tificial heart has celebrated its 35th anniversary [6]. Nitin-
Figure 2
Animal implant of the Atripump. The concave part is assumed to
touch atrium’s epicardium. When ON, the dome reduces its depth
pushing down the atrial wall. When OFF, the dome returns to its
rest position allowing atrial filling.
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ol wires were arranged in waves and placed around the
ventricles. Animal results were encouraging, but material
fatigue, excessively slow contraction and thermal injury
proved to be insurmountable problems at that time. Today,
we have commercially available Nitinol that has a lifetime
of billions of cycles and transitional temperature compat-
ible with human body implants.
Atripump for the treatment of chronic atrial
fibrillation
Atrial fibrillation (AF) is the most common cardiac ar-
rhythmia in over 50 year-olds and causes up to a 15% re-
duction in left ventricular ejection fraction. Moreover, be-
cause blood pools in the atria, in about 5% of patients clot-
Figure 3
The external bi-ventricular assist device comprises a skeleton of
carbon fibre (black bands) and a mesh (yellow) of aramidic fibres.
The carbon fibre follows the interventricular septum, the atrio-
ventricular groove, and encircles the cardiac apex. Zig-zagging
through the aramidic tissue are interwoven nitinol fibres, which are
joined to the carbon skeleton at the apex of the heart and then
spiral around the ventricles to the atrio-ventricular groove level.
Figure 4
The urinary sphincter is made of 3 silicon rings (green part) whose
diameter decreases when the nitinol fibre (black springs) is
activated. The rings are placed around the urethra. Up to 5 rings
could be placed to ensure the optimal control of urinary flow
reducing the risk of urethra lesions.
ted blood dislodges causing stroke, therefore lifelong an-
ticoagulation therapy is recommended [7]. Consequently,
patients with chronic AF suffer from cardiac failure and
have a high risk of thrombo-embolic events. Treatment of
AF consists primarily of palliation, mostly in the form of
pharmacological intervention aimed at reducing the risk of
stroke using anticoagulant agents. The only surgical inter-
vention that potentially cures AF rather than palliates, is
the Maze procedure. However, the rate of restoring atrial
contraction is low [8]. Patients continue to require anti-
coagulation therapy for life and, thus are exposed to the
risk of haemorrhagic complications. We first introduced the
concept of an Atrial Assist Device and developed the re-
lated device called Atripump to definitely restore the pump
function of the atrium in patients suffering of chronic AF
[9–12]. Atripump is a dome shape silicone coated nitin-
ol actuator 5 mm high, mounted on a plastic ring 55 mm
in diameter. Once electrically heated, nitinol wires reduce
their length causing a reduction of the dome concavity.
Current cut off produces wire elongation and the recovery
of the initial concavity of the dome. The changes in dome
concavity result in volume displacement. This cycle is con-
trolled by a pacemaker-like unit that senses ventricular
activity and gives current to the wires following a dedicated
algorithm. The dome is sutured onto the atrium’s epicar-
dium in order to provide the mechanical support to blood
circulation (fig. 2). Because there is no contact between
the assist device and host blood, no anticoagulation therapy
is required. This surgical approach could increase cardiac
output up to 10% as measured in several animal studies [11,
12] and should significantly improve the quality of life of
patients suffering from chronic AF. Moreover, the device
actively washes blood out of atria reducing the risk of clot
Figure 5
Illustration of a left eyelid sling that is attached to the electroactive
polymer artificial muscle device (EPA) after passing through an
interpolation unit is implanted in the lateral orbital wall (note screw
fixation). The power supply and artificial muscle are implanted in
the temporal fossa. Conceptually, when the normal right eyelid
blinks, the electrical sensor (green) sends a signal to the battery to
activate the EPA.
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formation and systemic embolism, making anticoagulation
treatment unnecessary. The heating issue that has always
been one of the major limitations for human applications of
nitinol actuators has considerably lost its importance. It is
true that, when the dome is activated in air at room tem-
perature, the silicon membrane reaches temperature above
50 °C making it incompatible with human implantation.
However, when the dome is in contact with liquids, such
as the blood in cardiac chambers, heat dissipates so quickly
that silicon membrane temperature stays above 35 °C. In
an elegant study published in 1988, Emoto and co-workers
reported the effects on surrounding tissue of heat dissip-
ation associated with thermally powered LVAS implant-
ation [13]. Systemic (affecting the lungs, kidneys, blood
tissue, and coagulation processes) and local effects of 20
W heat-dissipation were analysed in 5 calves. Conclusions
were that heat promoted neointima proliferation at the in-
terface pump-blood flow and angiogenesis was observed in
the tissue capsule adjacent to the heat- dissipating surface.
However, no deleterious systemic or local effects of 20 W
heat-dissipation were reported. Based on these results, we
could speculate that also the heat dissipated by the dome
will not cause systemic or local damage. The atrium and
the blood circulating in it will work as heat exchange keep-
ing the membrane temperature in a range compatible with
human implantation.
External compression of failing heart: artificial
cardiomyoplasty
Artificial muscle technology has allowed the construction
of a bi-ventricular assist device (BiVAD) that is able to re-
store ventricular pumping function through external com-
pression. Current ventricular assist devices (VADs) are
pneumatic/rotary pulsatile pumps based on non-compliant
chamber into which the blood is forced, or magnetically
suspended propellers that generate continuous flow once
placed into the blood stream [14]. Pulsatile pumps are
heavy which could causes surrounding tissue damage, have
extensive thrombogenic surfaces exposed to blood making
anticoagulant therapy mandatory and are associate with a
high incidence of life-threatening infections [18]. Continu-
ous flow pumps are associated with fewer complications
than pulsatile ones because they are smaller with less
thrombogenic surface exposed to blood, but can be used
only to assist the left circulation [14]. None of these
devices is able to assist both ventricles, which means that if
the patient needs biventricular assistance, two pumps have
to be implanted. External ventricular compression provided
by cardiomyoplasty is the most physiological way to im-
prove pump function in a diseased heart, particularly in
cases of dilated cardiopathy [19, 20]. Any device able to
reproduce external cardiac compression (artificial cardi-
omyoplasty) could potentially overcome the drawbacks of
the existing VADs.
The BiVAD consists of Nitinol wires woven in aradimic
tissue and connected to a carbon fibre skeleton that re-
produces the mechanical function of the interventricular
septum (fig. 3). Wire contraction induces the shortening
of the aramidic tissue that compresses the ventricles. In-
creasing the contact surface permits a redistribution of the
strength over a larger surface avoiding organ injury. The
skeleton enables an asymmetrical operation between left
and right ventricle. The number of wires and the amplitude
of pumping movement changes according to the severity of
right and left heart failure. Each ventricular assist device
can be arranged with 1 to 5 separate levels of wires modu-
lating the compressing force. An electronic control unit ac-
tivates wire contraction in a dedicated mode for each vent-
ricle. The total power consumption of the device is 10W.
This device has been tested in a bench model of diseased
heart [21] and provided 12% improvement of left ventricu-
lar ejection fraction and up to 20% improvement in right
ventricular function. Like human muscle fibre, the force of
contraction increases when the preload increases following
the Frank-Starling law.
The key advantages of artificial cardiomyoplasty could be
summarised as follow:
1) The absence of blood exposed thrombogenic surfaces
makes the anticoagulant therapy unnecessary avoiding
bleeding and embolic events.
2) One device provides independent compression of the
right and left ventricle. The control unit can modulate
compression force, compression rate and ejection
fraction of each ventricle independently, providing the
most compliant cardiac assist device ever developed.
3) It is easy to implant and does not require
cardiopulmonary bypass in contrast to all other VADs.
4) In case it fails, the residual ventricular function is not
affected as would happen if a continuous axial flow
pump stopped working, where the equivalent of severe
aortic regurgitation arises.
The First planned application of the BiVAD is to help the
weaning from extracorporal circulation in paediatric pa-
tients with congenital heart disease as an alternative to
more invasive Extra Corporal Membrane Oxigenator treat-
ment.
Artificial sphincters and peristaltic conduits
Artificial urinary sphincter
Urinary incontinence is a common and often embarrassing
problem and is due to functional impairment of muscles
and nerves that help to hold or release urine. Treatment of
urinary incontinence depends on severity and the degree of
response to a particular treatment. For patients with mild
symptoms there are a variety of treatments ranging from
pads, exercises to strengthen pelvic floor muscles and pess-
aries. Anti-cholinergic and Alpha-adrenergic drugs such as
pseudoephedrine may be prescribed for advanced incontin-
ence. For patients suffering from more severe symptoms
hormone replacement therapy is sometimes prescribed to-
gether with anti-depressants and in case of severe incontin-
ence, surgery is necessary. The surgical approach consists
of constructing sub-urethral slings from existing muscles,
or implantation of an artificial urinary sphincter [14]. For
over 30 years, physicians worldwide have implanted the
AMS 800 device in more than 100,000 men as a treatment
for stress urinary incontinence due to prostatectomy. The
AMS 800 is an implantable, fluid-filled, solid silicone
elastomeric device used to treat incontinence arising after
radical prostatectomy. The system simulates normal
sphincter function by opening and closing the urethra, un-
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der patient control. The patient opens the sphincter using
a remote control following the natural stimulus. However,
there are a number of drawbacks including the need for fre-
quent mechanical revisions, strict patient selection, optim-
al preoperative bladder management and regular follow-
ups. Even when these criteria are respected, successful
outcomes are regarded as low. In a variety of studies revi-
sion of the device occurred on average in 39% of patients,
urethral erosion in 5%, infection in 3%, and mechanical
failure in 15% [15].
Another medical device for treatment of male stress in-
continence after prostatectomy is ProACT (Proactive Ad-
justable Continence Therapy) (Uromedica). ProACT is a
minimally invasive urological implant designed to treat
male patients who have stress urinary incontinence arising
from intrinsic sphincter deficiency following radical pro-
statectomy for prostate cancer or transurethral resection
of the prostate (TURP) for benign prostatic hyperplasia
(BPH). ProACT therapy offers a first-line treatment option
for post-prostatectomy incontinence before invasive sur-
gical consideration or implant of an Artificial Urinary
Sphincter (AUS) or adjustable sling. Again there are simil-
ar disadvantages owing to the need for frequent mechanical
revisions. These systems are both designed to exert a con-
stant pressure on a very limited region of the urethra fre-
quently leading to tissue erosion, ischaemia, scarring, nec-
rosis and infection. This is the main reason why their use is
rarely indicated.
An innovative approach is to use smart material switching
the compressed area of the urethra in order to achieve con-
tinence. This is called the “piano” concept and is realised
by assembling 3 to 5 shutter units over a predetermined
length and position along the urethra. These shutters func-
tion in pairs with modulated alternation of their open and
closed positions over time, such that the above-mentioned
problems due to constant compression are greatly reduced
or even eliminated. An implantable control unit having di-
mensions similar to current cardiac pacemakers drives the
system. Figure 4 details the technical aspects of the device.
This sphincter has been extensively tested in an animal
model [22]. The device was positioned around the urethra
of male sheep and the control unit was placed 5 cm away,
under the skin, through a second incision. The sphincter
was open each hour for a period of 10 minutes to guaran-
tee urination. This study defined the in-bladder leak point
pressure and the tissue tolerability of the device. To meas-
ure the in-bladder leak point pressure the bladder was filled
with saline while just one ring was closed and bladder pres-
sure was monitored. To verify tissue tolerability, animals
were sacrificed after 2, 5 and 9 weeks and two biopsies
around the cuffs were analysed. Sections of urethra not sur-
rounded by a cuff were taken as controls. Provoked in-
continence occurred at a bladder pressure over 1 bar. The
closing force of the cuff was approximately 0.7N. No clin-
ical infection occurred. Histological investigation showed
no signs of infection, scarring or atrophy. No difference in
tissue structure and organisation of the urethra with and
without the artificial sphincter was observed. This animal
study showed that the artificial urinary sphincter based on
smart materials can provide continence and has good tissue
tolerability short term [22].
The eyelid sling
Electroactive polymer artificial muscle is an emerging
technology that has the potential to be used in rehabilitating
facial movement in patients with paralysis. Blinking is an
essential part of maintaining a healthy eye. The lid wipes
the surface of the eye clean and spreads tears across the
cornea. Without this lubrication, the eye is soon at risk of
developing corneal ulcers that eventually can cause blind-
ness. Over 40’000 cases of facial paralysis are seen in the
United States every year, with most of these being idiopath-
ic (Bell’s palsy) or virally induced [16]. In the few cases
of a facial paralysis in which the patients do not recover,
a variety of surgical options can be used to maintain fa-
cial muscle tone, rehabilitate some function, and protect the
globe from exposure keratopathy. These surgical options
include facial nerve grafting, cable grafting (sural nerve),
cross-face jump grafts, or anastomosis with other cranial
nerves (hypoglossal-facial nerve). However, in many cases
of permanent facial paralysis, nerve grafting may not be
possible owing to, (a) extensive tumour excision, includ-
ing the facial nerve or distal facial muscles; (b) permanent
facial nerve dysfunction after Bell’s palsy or herpes zoster
palsy; or (c) congenitally absent facial nerve function with
multiple other cranial neuropathies (Mobius syndrome).
Surgeons from UC Davis Medical Center have demon-
strated that artificial muscles can restore blinking in pa-
tients with facial paralysis [23]. Their first priority was to
determine if the stroke and load requirements of the eyelid
sling mechanism were within the specifications of artificial
muscle. They measured the force required to close the eye-
lid in cadavers that was approximately 1500 to 1800 mN,
and then the force requirement for closing the eyelid with
the temporalis fascia sling (627 ± 128 mN) and with the
ePTFE eyelid sling (1347 mN ± 318 mN; P < .05). These
values were within the range of force developed by EAP.
Then, they used an eyelid sling mechanism to create an
eyelid blink actuated by an artificial muscle. The technique
consists of inserting a sling made of EAP around the eye.
Small titanium screws secure the eyelid sling to the small
bones of the eye. The sling is connected to a control unit
and a battery supply (fig. 5). The artificial muscle device
and battery were placed in the natural hollow (fossa tem-
poralis) of the temple to disguise their presence. The dis-
placement of the eyelid sling that was required for com-
plete eyelid closure was 3 mm when both a lower and upper
eyelid sling was used, and 6 mm with the solitary upper
eyelid sling. In a real setting, a myoelectric sensor could be
placed in electrical contact with the actuator to provide a
signal from the contralateral orbicularis oculi muscle to co-
ordinate eyelid blinking.
In conclusion, the eyelid sling concept was successful at
creating eyelid closure in a cadaver model. The stroke re-
quirements of the proposed artificial muscle device were
within the range of available EPAM technology. Future
aims include consideration of different sling materials and
development of both the EPA device and the articulation
component, which is planned for the lateral orbital rim.
Biocompatibility and durability studies of EPA in a gerbil
model are under way. This technology will be available for
patients within the next five years. For people with oth-
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er types of paralysis, the use of artificial muscles could
someday mean regaining the ability to smile.
Artificial peristaltic oesophagus
The oesophagus is not a simple tube for passage of food; it
actively transports the food by peristalsis. One can swallow
food against gravity, for instance, while doing a handstand.
Dysfunction of peristalsis leads to aspiration of food lead-
ing to life threatening complications. Without the peristalt-
ic function, an artificial oesophagus has no practical use.
Artificial muscles could be used to construct an artificial
oesophagus with peristaltic movement and a lower oeso-
phageal sphincter to replace the diseased oesophagus. This
approach would also avoid the need for laparotomy to mo-
bilise the stomach or intestine thereby reducing the com-
plexity of the operation.
The artificial oesophagus that was developed by Yambe’s
team consisted of a Gore-Tex vascular graft and a nickel-ti-
tanium shape memory alloy (SMA) coil [24]. Serial paired
SMA coils were placed continuously around the artificial
vascular graft in an annular manner. Each pair was con-
nected to an electrical circuit consisting of memory relay
switching. The device has been tested in an animal model
[24]. After implantation into the neck of a goat, peristaltic
movement was generated in the artificial oesophagus by
contraction of the NiTi-SMAs, triggered by a pressure
sensor in the proximal part of the tube. The simulated peri-
staltic movement was similar to the peristaltic movement
observed in the x-ray barium study performed in humans.
However, this device needs more technical improvements
and extensive animal studies, before reaching the preclinic-
al phase.
With the availability of an artificial oesophagus, oesopha-
geal carcinoma surgery will become easier and less invas-
ive, and it will be possible to perform the surgery entirely
by thoracoscopy. It will widen the indications for an oe-
sophageal operation such that more patients, including the
elderly, can benefit from the operative treatment.
Conclusions
We reviewed some of the clinical applications of these
amazing technologies demonstrating that in the future it
will be possible to integrate smart devices into the human
body, thereby creating “human chimera”. Artificial organs
will eventually avoid some of the problems related to organ
transplants like shortage of donors or immunosuppression
with the advantage of improving the quality of life even
in severely diseased patients, not eligible for transplant.
However, to face all the technical challenges of artificial
organs, researchers with a diversity of scientific back-
grounds have to work closer than ever and this is the real
revolution of the future medicine.
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Figures (large format)
Figure 1
The above curves illustrate the extension relationship of a muscle that is stretched (left) and an SMA spring actuator (right) at different
temperatures. The idea in this comparison is to identify a hysteresis loop in both cases. Left: typical stress–muscle length extension
relationships, measured during 6 Cycles of 5, 10 and 15% length extension at 25 μm s−1. Right: isothermal force-displacement curves of an
SMA spring actuator.
Figure 2
Animal implant of the Atripump. The concave part is assumed to touch atrium’s epicardium. When ON, the dome reduces its depth pushing
down the atrial wall. When OFF, the dome returns to its rest position allowing atrial filling.
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Figure 3
The external bi-ventricular assist device comprises a skeleton of carbon fibre (black bands) and a mesh (yellow) of aramidic fibres. The carbon
fibre follows the interventricular septum, the atrio-ventricular groove, and encircles the cardiac apex. Zig-zagging through the aramidic tissue are
interwoven nitinol fibres, which are joined to the carbon skeleton at the apex of the heart and then spiral around the ventricles to the atrio-
ventricular groove level.
Figure 4
The urinary sphincter is made of 3 silicon rings (green part) whose diameter decreases when the nitinol fibre (black springs) is activated. The
rings are placed around the urethra. Up to 5 rings could be placed to ensure the optimal control of urinary flow reducing the risk of urethra
lesions.
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Figure 5
Illustration of a left eyelid sling that is attached to the electroactive polymer artificial muscle device (EPA) after passing through an interpolation
unit is implanted in the lateral orbital wall (note screw fixation). The power supply and artificial muscle are implanted in the temporal fossa.
Conceptually, when the normal right eyelid blinks, the electrical sensor (green) sends a signal to the battery to activate the EPA.
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